Description
Product Description: Genesis Meds Drostanolon Prop 100mg 10ml
Genesis Meds Drostanolon Prop 100mg 10ml is a high-quality anabolic steroid designed specifically for athletes and bodybuilders. This product is formulated to enhance performance, promote muscle growth, and improve overall physical strength.
Features and Benefits:
- Enhances athletic performance
- Promotes lean muscle growth
- Increases strength and endurance
- Improves muscle definition and hardness
- Boosts metabolism for efficient fat burning
- Enhances vascularity and muscle pumps
Possible Side Effects:
- Acne
- Hair loss
- Increased aggression
- Changes in cholesterol levels
- Suppression of natural testosterone production
Uses and Dosage for Bodybuilders:
Genesis Meds Drostanolon Prop 100mg 10ml is commonly used by bodybuilders during cutting cycles to achieve a ripped and shredded physique. The recommended dosage for male athletes is typically 300-500mg per week, divided into two equal doses. Female athletes should use a lower dosage of 50-100mg per week to minimize the risk of virilization.
Indications and Contraindications:
This product is indicated for individuals who are looking to improve their athletic performance, increase muscle mass, and achieve a more defined physique. However, it is important to note that Genesis Meds Drostanolon Prop 100mg 10ml is not suitable for everyone. It should not be used by individuals with pre-existing medical conditions, such as liver or kidney problems, cardiovascular diseases, or prostate cancer. Pregnant or breastfeeding women should also avoid using this product.
Value to the Buyer:
By purchasing Genesis Meds Drostanolon Prop 100mg 10ml from our website, you can be assured of receiving a genuine and high-quality product. We prioritize customer satisfaction and offer fast and discreet shipping to ensure a hassle-free experience. Our competitive pricing and secure payment options make buying from our website a convenient and reliable choice for athletes and bodybuilders.
Reviews
There are no reviews yet.